Sign in

    Kim Kelderman

    President and CEO at Bio-Techne Corp
    Since February 1, 2024
    Age
    57 years
    Education
    Earned a B.S. in Applied Sciences from Hogeschool Heerlen in the Netherlands.
    Tenure
    Joined TECH on April 30, 2018, as President of the Diagnostics and Genomics Segment, served as COO starting November 1, 2023, and was promoted to President and CEO on February 1, 2024.

    Also at Bio-Techne Corp

    JH
    James Hippel
    EVP and CFO
    MM
    Matthew McManus
    President, Diagnostics and Genomics
    SB
    Shane Bohnen
    SVP, General Counsel, and Corporate Secretary

    About

    Kim Kelderman is a seasoned executive with over 30 years of experience in the life sciences industry, having held significant leadership roles at major companies such as Thermo Fisher Scientific and Becton Dickinson. His career is marked by a deep operational understanding and a consistent record of driving sustainable growth through strategic innovation and excellence in execution.

    At TECH, his pivotal contributions include leading the Diagnostics and Genomics Segment to commercialize breakthrough products like the ExoDx Prostate test, which was instrumental in driving significant volume growth, as well as doubling revenue in the spatial biology business. He also played a key role in successful acquisitions, which positioned the business for robust growth through new product introductions and strategic partnerships.

    Beyond his operational achievements, his leadership style has been characterized by a focus on integration and execution of mergers and acquisitions, further complemented by his involvement on the Board of Directors for StatLab Medical Products. His comprehensive approach to strategic growth and market expansion continues to shape TECH’s trajectory in highly dynamic and underpenetrated markets.

    $TECH Performance Under Kim Kelderman

    Past Roles

    Organization Role Date Range Details
    Bio-Techne President, Diagnostics and Genomics Segment 2018 - Feb 1, 2024 Completed Asuragen and Lunaphore acquisitions; commercialized the ExoDx Prostate test; doubled the revenue of the spatial biology business
    Thermo Fisher Scientific Leader, Genetic Sciences Division (Platforms and Content) N/A Managed Instrumentation, Software, Consumables, and Assays businesses including Applied Biosystems and legacy Affymetrix
    Becton Dickinson Senior Segment Leader N/A Managed the Blood Tubes "Vacutainer" business

    External Roles

    Organization Role Date Range Details
    StatLab Medical Products Independent Director N/A N/A

    Fixed Compensation

    Data from  FY 2024
    Component NameAmount ($)Payment ScheduleAdditional Details
    Base Salary$759,511Prorated over 2024Based on time served as non-CEO with an annualized CEO salary of $900,000.
    Cash Severance Upon Termination$1,659,511Paid upon termination without cause or resignation for good reason (trigger assumed at end of FY2024)Includes a base salary multiple, earned non‐equity incentive compensation, unvested cash performance units, and COBRA health insurance premiums.
    Time-Based Stock Options$2,965,857Grants on August 15, 2023; November 1, 2023; and February 1, 2024Granted with fair values of $924,008 (29,391 options at $84.61), $750,164 (38,252 options at $52.83), and $1,291,686 (51,890 options at $68.54).
    Time-Based Restricted Stock Units$749,975Grant on November 1, 202314,196 RSUs granted at a market value of $52.83 per share.

    Performance Compensation

    Data from  FY 2024

    Performance-Based Stock Options

    Grant DateThreshold OptionsTarget OptionsMaximum OptionsGrant Date Stock PriceGrant Date Fair Value ($)
    August 15, 20237,34814,69522,043$84.61$692,998
    February 1, 20248,64817,29725,945$68.54$645,843

    Vesting: Awards vest following fiscal year 2026 upon achievement of consolidated adjusted operating income and adjusted revenue growth targets.

    Performance-Based Restricted Stock Units (RSUs)

    Grant DateThreshold ($)Target ($)Maximum ($)Grant Date Stock PriceGrant Date Fair Value ($)
    February 1, 2024$446,298$892,595$1,338,893$68.54$645,843

    Vesting: RSUs vest contingent on the achievement of performance goals by fiscal year 2026.

    Performance-Based Cash Bonus

    MetricThresholdTargetMaximumWeight
    Company Organic Revenue$1,126.5M$1,185.8M$1,221.4M50%
    Adjusted Operating Income$397.4M$418.3M$439.2M50%

    Bonus Amounts:

    • Target Bonus: $784,050 (110% of annual salary of $759,511).
    • Threshold Bonus: $196,013 (25% of target bonus).
    • Maximum Bonus: $1,568,100 (200% of target bonus).

    Payment: Bonus is determined based on fiscal year 2024 performance and is paid in the subsequent fiscal year.

    Performance-Based Long-Term Incentive Awards (August 15, 2023)

    ComponentThresholdTargetMaximumGrant Date Fair Value ($)Grant Date Stock Price
    Stock Options7,34814,69522,043$461,999 $84.61
    RSUs2,7305,4618,191$462,027 $84.61

    Vesting: Vest after fiscal year 2026 based on performance metrics tied to consolidated adjusted operating income and revenue growth.

    Performance-Based Long-Term Incentive Awards (February 1, 2024)

    ComponentThresholdTargetMaximumGrant Date Fair Value ($)Grant Date Stock Price
    Stock Options8,64817,29725,945$430,562 $68.54
    RSUs3,1416,2829,423$430,568 $68.54

    Vesting: Awards vest following fiscal year 2026, with grants proration reflecting the partial year as CEO.

    Performance-Based Cash Performance Units

    Payout LevelThreshold ($)Target ($)Maximum ($)
    Cash Units$2,867$5,734$8,601

    Vesting: Cash performance units vest after fiscal year 2026 if the company meets adjusted operating income and revenue growth goals. They also compensate for dividends paid during the vesting period.